Now live: Pro — the full 13F research suite for serious investorsSee pricing →
← Tracker

Institutional

BOONE CAPITAL MANAGEMENT LLC

CIK 0001882053
$326.4M
Reported AUM
13
Positions
Q1 2026
Period
2026-05-15
Filed

The Brief · BOONE CAPITAL MANAGEMENT LLC · Q1 2026

AI · grounded in 13F

BOONE CAPITAL MANAGEMENT LLC established a new position in TFX valued at $33.3M. The fund also opened new stakes in GRDN for $23.8M and ASTRAZENECA PLC for $21.7M. On the sell side, the manager closed its position in NBIX, reducing exposure by $21.5M. Additional exits included HQY and RAPT.

Portfolio · Q1 2026

MIRM$38.9MIONS$37.6MCI$36.7MMDT$34.5MTFX$33.3MBMRN$30.9MGRDN$23.8MAZN$21.7MUNH$21.4MBBIO$17.0MAVNS$16.6MKODBL

Top holdings

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1MIRMMIRUM PHARMACEUTICALS INC$108.040.44%106.79%561.97%$38.9M11.92%HELD
2IONSIONIS PHARMACEUTICALS INC$53.70-0.63%25.59%35.92%$37.6M11.51%HELD
3CITHE CIGNA GROUP$285.82-3.59%15.56%53.58%$36.7M11.24%HELD
4MDTMEDTRONIC PLC$86.51-1.18%1.17%-23.30%$34.5M10.57%HELD
5TFXTELEFLEX INCORPORATED$132.38-1.68%17.52%-64.74%$33.3M10.22%HELD
6BMRNBIOMARIN PHARMACEUTICAL INC$60.76-0.99%4.55%-27.81%$30.9M9.48%HELD
7GRDNGUARDIAN PHARMACY SVCS INC$41.832.05%101.62%128.87%$23.8M7.28%HELD
8AZNASTRAZENECA PLC$170.15-1.82%19.22%63.87%$21.7M6.65%HELD
9UNHUNITEDHEALTH GROUP INC$414.04-1.55%83.63%11.52%$21.4M6.57%HELD
10BBIOBRIDGEBIO PHARMA INC$81.47-2.47%77.69%67.97%$17.0M5.21%HELD
11AVNSAVANOS MED INC127.60%-24.27%$16.6M5.09%HELD
12KODKODIAK SCIENCES INC$41.483.67%501.65%-57.52%$10.7M3.29%HELD
13TENXTENAX THERAPEUTICS INC$15.021.35%138.26%-99.42%$3.2M0.98%HELD

Source: SEC EDGAR · accession 0001214659-26-006448. 13F discloses long positions only — shorts, foreign equities, and options are excluded.